Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Psychedelic Medicine topic
No spam. Unsubscribe anytime.
Committee to hear public testimony on psychedelic medicine after S.197 discussion
Summary
The committee announced it will take testimony on psychedelic medicine following work on S.197 and noted a recent executive order to accelerate clinical trials; several national figures were named as potential, not confirmed, witnesses.
After finishing floor discussion of S.197, the chair announced the committee would take testimony on psychedelic medicine and referenced a recent presidential executive order designed to fast‑track clinical trials.
The chair said the committee might hear from national figures and that some experts could be willing to travel to Vermont with enough notice; Michael Pollan and other high‑profile names were mentioned informally as potential participants but no invitations or confirmations were recorded on the record. The announcement framed the item as an informational testimony session rather than a final action.
What happens next: The committee planned to hear testimony on psychedelic medicine following the immediate session; members said they would coordinate scheduling and witnesses in the coming weeks.
